Deals

News Photos

Bristol Myers' Opdivo with Exelixis drug cuts kidney cancer death risk - study
Click on the image below to view in Stereo 3D

Bristol Myers' Opdivo with Exelixis drug cuts kidney cancer death risk - study
Bristol Myers Squibb Co's cancer immunotherapy Opdivo in combination with Exelixis Inc's Cabometyx reduced the risk of death by 40% in previously untreated patients with advanced kidney cancer, according to data from a late-stage study to be presented on Saturday. The drug combination also doubled patients' median length of time before their cancer began to worsen to 16.6 months compared to progression-free survival of 8.3 months for patients treated with the chemotherapy sunitinib, an older Pfizer Inc drug sold under the brand name Sutent. 'There is no doubt in my mind that this will be a major player' as an initial treatment for advanced kidney cancer, said lead researcher Dr. Toni Choueiri from Dana-Farber Cancer Institute in Boston.
More Description
Image URL

 
 
 
vlrPhone
vlrFilter
vlrMemos

Project of very low consumption, radiation and bitrate softphones
Multifunction Audio Filter with Remote Control
App to measure the quality of the voice
More Information
Free the Animation VR
AR

Play to reveal 3D images and 3D models
More Information

WhmSoft Moblog
Copyright (C) 2006-2020 WhmSoft
All Rights Reserved